“Suffocating” tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy

Bassam Janji*, Salem Chouaib

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)

Abstract

We recently reported that inhibiting Hypoxia-inducible Factor-1α (Hif1a) transcriptional activity improves melanoma immunotherapy by driving immune cells into the tumor microenvironment (TME). This Author’s View provides additional perspectives on how hypoxia inhibitors combined with immunotherapy can be used as innovative approaches to improve the therapeutic benefit of melanoma patients.

Original languageEnglish
Article number1968611
Pages (from-to)1968611
JournalOncoImmunology
Volume10
Issue number1
DOIs
Publication statusPublished - 7 Sep 2021

Keywords

  • CCL5/Rantes
  • CD8 T-lymphocytes
  • Hypoxia
  • NK cells
  • anti-PD-1/PD-L1
  • cancer immunotherapy
  • chemokines
  • cold/hot tumors
  • hypoxia-inducible factor
  • immune landscape
  • melanoma

Fingerprint

Dive into the research topics of '“Suffocating” tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy'. Together they form a unique fingerprint.

Cite this